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Abstract 
We describe the case of a never-smoker who received second-line erlotinib as a 
treatment for his non-small cell lung cancer. Within one month, acute hepatic failure 
developed as well as a thrombotic-thrombocytopenic microangiopathy, with fatal 
outcome. In patients with non-small cell lung cancer, hepatic toxicity of erlotinib is a rare 
but severe complication; so far three fatal cases have been reported. Patients’ liver 
function should be assessed before starting erlotinib and special care is recommended if 
pretreatment bilirubin is elevated. 
Erlotinib (Tarceva) is an oral, reversible epidermal growth factor receptor (EGFR) 
tyrosine-kinase inhibitor. The drug was approved by the FDA in 2004 for treatment of 
patients with locally advanced or metastasized non-small cell lung cancer (NSCLC) and in 
2005, in combination with gemcitabine, for treatment of patients with pancreatic cancer, 
both on the basis of randomized phase III studies [1, 2]. In a clinical phase I study, a daily 
dose of 150 mg proved to be the maximum tolerated dose, the dose-limiting toxicities 
being diarrhea, skin reactions und fatigue [3]. Serious liver dysfunction was rarely found 
in phase III studies [1, 2, 4]. However, in the last two years there have been a number of 
case reports on acute, severe liver toxicity with erlotinib [5, 6], a few with a fatal outcome 
[7, 8]. We are describing the case of a patient with metastasized NSCLC, who developed 
acute liver failure with a fatal coagulation complication under erlotinib treatment. 
Case Report 
A 53-year-old never-smoker was diagnosed with a deep leg vein thrombosis and one month later 
with an adenocarcinoma of the lung (negative for EGFR mutation and EML4-ALK translocation), stage 
IVB with a malignant pleural effusion. A nonproductive cough had been the only symptom. 
Anticoagulation with low molecular weight heparin (LMWH) was started, overlapping with 
phenprocoumon. A palliative chemotherapy with 4 cycles of cisplatin/vinorelbine was given, which  
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resulted in a partial remission. Ten weeks later, the patient complained of a deterioration of his 
performance status, and pulmonary and pleural tumor progression as well as the suspicion of a new 
liver metastasis were diagnosed (fig. 1a). Laboratory results showed an anemia of 115 g/l, otherwise 
normal hematology; ASAT/ALAT, alkaline phosphatase and creatinine were within the normal range, 
bilirubin 19 μmol/l (<17), LDH 587 U/l (<450). A second-line therapy with a daily dose of 150 mg 
erlotinib was started. 
On the ninth day of therapy, the patient was bedridden, complained of lack of appetite and reported 
being unable to walk. Clinically, he was in a bad general condition with a performance status 3. A 
discrete folliculitis of the thoracic aperture and a relapse of the leg vein thrombosis were found, but 
there was no evidence of neurological pathologies. Phenprocoumon was stopped and LMWH was 
resumed in a therapeutic dose. The laboratory results showed constant anemia, discrete signs of 
cholestasis, further elevated lactate dehydrogenase (LDH) and minor renal insufficiency. The 
transaminases were not measured. We interpreted the general condition to be a consequence of the 
tumor and the recurring deep vein thrombosis. Erlotinib was continued. 
On the 17th day of therapy, the patient was hospitalized due to further deterioration of his general 
condition, with a fever of 39.6°C, vomiting and upper abdominal pain. A slight anemia of 110 g/l was 
found, Lc were 11.7 × 10
9/l, Tc 291 × 10
9/l, INR 4.55, bilirubin 20 μmol/l, alkaline phosphatase 475 U/l, 
LDH 1,856 U/l, ASAT 1,011 U/l, ALAT 2,050 U/l, creatinine 120 μmol/l, CRP 132 mg/l (fig. 2). Blood 
cultures and serologies for hepatitis A, B and C were negative. 
The abdominal ultrasound showed a severely inhomogeneous liver, as well as progression of the liver 
metastasis in segment II and thickening of the gall bladder. The differential diagnosis at this point was 
acute hepatitis or cholangitis and an antibiotic therapy with ciprofloxacin und metronidazole was 
initiated. Erlotinib was stopped since drug-induced hepatitis could not be excluded. 
On day 24 after starting erlotinib, the patient complained of excruciating pain in his right upper 
abdomen. Another rise in temperature was documented. The lab results showed an anemia of Hb 118 
g/l, Lc 21.9 × 10
9/l, Tc 134 × 10
9/l, some fragmentocytes, INR 1.68, fibrinogen 1.7 g/l (2–4), factor II 49% 
(70–120), factor V 64% (70–140), bilirubin 80 μmol/l, alkaline phosphatase 814 U/l, LDH 5,841 U/l, 
ASAT 3,511 U/l, ALAT 884 U/l, creatinine 100 μmol/l, CRP 149mg/l (fig. 2). A CT scan revealed a 
pulmonary and pleural tumor progression, edema of the gallbladder and also fresh hypodense areas in 
the liver and hypodensities of the kidney and the upper pole of the spleen, which were interpreted as 
necrosis (fig. 1b). Sonographically, the portal vein was dilated. The patient was put on hydration, and 
allopurinol and vitamin K were given; LMWH was continued. 
On day 30, acral necrosis of the toes was found. All peripheral pulses were palpable. The lab results 
showed constant anemia with elevated reticuloytes 276 × 10
9/l (35–105), a further drop in factor V, 
antithrombin III 23% (75–120), haptoglobin 0.2 g/l (0.6–3.6), a negative result in the PF4 antibody and 
the direct Coombs test, an increase in bilirubin with unchanged alkaline phosphatase and declining 
transaminases (fig. 2). The diagnosis of thrombotic microangiopathy with compensated hemolysis was 
made and an antithrombin III substitution with fresh frozen plasma was started.  
A heparin-induced thrombocytopenia was ruled out because of the lack of PF4 antibodies. After 
unstoppable deterioration of his general condition, the patient died three days later. 
Consent 
The patient has unfortunately passed away and could not give his informed consent. There is no 
immediate family to be contacted. All patient data are completely anonymized. 
Discussion 
This unfortunate patient died of acute liver failure, most likely due to erlotinib. First, 
there was a rapidly progressive hepatopathy, which led to hospitalization 17 days after 
initiating erlotinib. The patient presented a clinical picture of acute hepatitis. A second 
row of events began on the seventh day of hospitalization with massive liver necrosis and 
signs of a blood coagulation disorder.  
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We attribute the acute hepatitis to the medication with erlotinib. The drug is 
metabolized hepatically through the enzymes CYP3A4 und CYP1A2 of cytochrome P450. 
Drug interaction can therefore affect the metabolism of erlotinib and possibly increase the 
toxicity. During the first week of therapy, the only other comedication the patient took 
was phenprocoumon. Phenprocoumon is partially inactivated by CYP3A4. When giving 
erlotinib and coumarines simultaneously, an increase in INR but not in erlotinib 
clearance has been described [12]. Consequently, we do not think that the combination 
was the cause of the described toxicity. 
The time course of the liver toxicity correlates with other documented case reports 
(table 1). Presently it is unclear why exclusively cases with lung cancer took a fatal course. 
Perhaps this is merely a quantitative problem; erlotinib is used in many more patients 
with NSCLC than in patients with other cancers. Alternatively, the dose of erlotinib might 
be relevant. In patients with pancreatic cancer, erlotinib was dosed mostly at 100 mg/day 
in combination with gemcitabine [2]. In this study, the grade 3/4 liver toxicities were 
comparable between gemcitabine alone and the combination of erlotinib and gemcitabine 
(grade 3 elevation of ASAT/ALAT 18 vs. 23%, of bilirubin 10% in both groups), and were 
likely to be tumor-related. In phase III studies in NSCLC patients, no [4] or just moderate 
liver enzyme increases (4% grade 2 vs. 0% [1]) were found. However, only patients 
without [1], or with liver enzyme increase grade ≤1 [4] were included in these trials. This 
is also the case for the phase I study [3], in which a therapy-associated bilirubinemia grade 
1 is described in 8/40 patients, but transaminases did not increase. More recent 
pharmacokinetic data of patients with preexisting liver function problems are not 
conclusive [9, 10]. The most significant factor to impair drug clearance seems to be 
increased bilirubin [9]. Miller et al. [10] come to the conclusion that patients with 
pretherapeutic liver dysfunction should be started on a reduced dose of erlotinib of 75 
mg/day. 
It is not known why a few patients react to erlotinib with such massive toxicity. 
Pharmacogenomical studies have shown polymorphisms on the CYP3A4- as well as on 
the CYP3A5-gene and have investigated their effect on the pharmacokinetics of erlotinib 
[11]. No clear correlation was found, not even on commonly observed toxicities such as 
exanthema or diarrhea. Further pharmacogenetic research is warranted. 
Recently published cases of acute liver toxicity under erlotinib have caused OSI 
Pharmaceuticals and Genentech to inform the physicians of this data in a ‘Dear Doctor’ 
letter in September 2008 and to amend the drug information accordingly. References to 
‘hepatotoxicity’ and ‘patients with hepatic impairment’ now appear in the chapter 
‘warnings’ [12]. Special caution is indicated in patients with pretreatment elevations of 
bilirubin, but no dose reduction of erlotinib is suggested. 
This patient’s course was complicated by a blood coagulation disorder. On the seventh 
day in the hospital, at the time of the massive liver necrosis, first symptoms of a 
microangiopathic and disseminated coagulopathy occurred: fragmentocytes, 
thrombocytopenia, diminished fibrogen as well as factor V. It can be assumed that the 
cause of the coagulation disorder was multifactorial, the extensive liver cell necrosis being 
an important contributing factor. Considering the patient’s history with a deep vein 
thrombosis as the first symptom of his malignancy, there was probably a tumor-
associated coagulopathy involved as well, which is a common paraneoplastic symptom, 
frequently seen in adenocarcinomas of the lung [13, 14]. A direct link between erlotinib 
monotherapy and coagulopathy seems less likely; there are no reports in the literature to 
support such a hypothesis. Two cases of patients with pancreatic cancer and treatment 
with erlotinib and gemcitabine who developed microangiopathic hemolytic anemia with  
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thrombocytopenia have been described; this complication was, however, most likely 
caused by gemcitabine [15]. Thus, we believe that the coagulopathy was not a direct 
consequence of erlotinib but rather an indirect effect of erlotinib-induced acute hepatitis. 
We are describing the third case of a fatal liver toxicity in a patient with 
adenocarcinoma of the lung under treatment with erlotinib. It is estimated that each year 
more than 100’000 patients receive erlotinib. Therefore, fortunately, this seems to be a 
very rare complication [16]. However, because of its severity, we think it is important that 
prescribing physicians know about this potential danger. We suggest monitoring liver 
function tests after initiating erlotinib, and stopping treatment if there is a suspicion of 
drug-induced hepatitis. Patients with preexisting elevations of bilirubin should be 
monitored with special care and in these patients reducing the dose of erlotinib could be 
considered [9, 10]. 
 
 
 
Table 1. Summary of published cases of erlotinib-induced acute liver toxicity 
 Diagnosis  Age/ 
sex 
Dose of  
erlotinib 
mg 
Concomitant 
drug 
Known liver 
function  
abnormality 
Time to first 
elevation  
LFT 
Outcome Time  to 
recover 
LFT 
Liu et al., 2007 
[7] 
lung cancer  67/F  150 
100 by 
reinduction
none  none  day 14  
day 10 after 
reinduction 
fatal  
Ramanarayanan  
and Scarpace, 
2007 [5] 
pancreatic  
cancer 
70/M  100  gemcitabine  none  day 14  recovered 6 weeks
Saif, 2008 [6] pancreatic   
cancer 
52/M 100  gemcitabine  none  week  7  recovered  8  weeks
Pellegrinotti et al., 
2009 [8] 
lung cancer  77/M  100  oral antidiabetic 
omeprazole 
prednisone 
furosemide 
none day  12  fatal   
Present case  lung cancer  53/M  150  phenpro- 
coumon 
liver  
metastasis 
day 10  fatal   
LFT = Liver function tests. 
 
 
 
  
Case Rep Oncol 2010;3:182–188 
DOI: 10.1159/000315366 
Published online: June 8, 2010  © 2010 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
186
Fig. 1. a 4 days before the initiation of therapy. b 24th day of erlotinib treatment. 
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Fig. 2. Evolution of laboratory parameters. 
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